252 related articles for article (PubMed ID: 32696192)
1. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
[TBL] [Abstract][Full Text] [Related]
2. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
[TBL] [Abstract][Full Text] [Related]
3. Taking stock of cost-effectiveness analysis of healthcare in China.
Butt T; Liu GG; Kim DD; Neumann PJ
BMJ Glob Health; 2019; 4(3):e001418. PubMed ID: 31179038
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
5. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
Silver MC; Neumann PJ; Ma S; Kim DD; Cohen JT; Nyaku M; Roberts C; Sinha A; Ollendorf DA
Vaccine; 2021 Nov; 39(46):6727-6734. PubMed ID: 34656380
[TBL] [Abstract][Full Text] [Related]
6. Costing and perspective in published cost-effectiveness analysis.
Neumann PJ
Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
[TBL] [Abstract][Full Text] [Related]
7. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
[TBL] [Abstract][Full Text] [Related]
8. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
10. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?
Feng X; Kim DD; Cohen JT; Neumann PJ; Ollendorf DA
Int J Technol Assess Health Care; 2020 Apr; 36(2):96-103. PubMed ID: 32340631
[TBL] [Abstract][Full Text] [Related]
11. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States.
Ross EL; Becker JE; Linnoila JJ; Soeteman DI
J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33211912
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Open Versus Endoscopic Carpal Tunnel Release.
Barnes JI; Paci G; Zhuang T; Baker LC; Asch SM; Kamal RN
J Bone Joint Surg Am; 2021 Feb; 103(4):343-355. PubMed ID: 33591684
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of total shoulder arthroplasty: a prospective health economic study using real-world data.
Grobet CE; Glanzmann MC; Eichler K; Rickenbacher D; Meier F; Brunner B; Audigé L
J Shoulder Elbow Surg; 2021 Sep; 30(9):1998-2006. PubMed ID: 33774171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
